BioSpace News Archive

The industry analysis report is considered a valuable source of information about the global UV Infection Control Device industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

Increasing prevalence of anaphylaxis, diabetes, migraine and rheumatoid arthritis across the globe, growing geriatric population, and rising preference for home care settings are some key factors expected to drive global market growth.

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), announces that Dr. Raffaele Baffa (“Dr. Baffa”) has been appointed as the Chief Medical Officer (“CMO”) of the Company, responsible for overseeing the global clinical development strategies and operations for the Company’s innovative pipeline product candidates.

Growing geriatric population worldwide and rising incidence of gastrointestinal disorders are among the key factors driving the global market revenue growth.

Funding used to boost development and start clinical trials in humans in 2023.

Helix BioPharma Corp., a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, announced the resignation of Dr. Krzysztof Saczek from the Board of Directors with immediate effect.

Lab Logistics Management, announced today the appointment of industry veteran Ruth Abdulmassih as Chief Executive Officer.

Life Sciences industry experts Michael D. Webb and Brian Cain bring extensive expertise in strategic pharmaceutical growth.

Anika Therapeutics, Inc. announced that the Company plans to issue its first quarter 2022 financial results after the close of the market on Thursday, May 5, 2022 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

New research in the April 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network found the rate of mammography use by breast cancer survivors has been steadily declining since 2009, particularly among younger survivors.